Three companies teaming together to create a DNA based test to determine which patients will benefit from selected drug treatments. The one for breast cancer is already available, so one more effort towards more information from the start and smarter clinical trials. BD
NEW YORK (GenomeWeb News) Transgenomic said today that it will work with Key Genomics to develop a molecular test to help physicians find out which ovarian cancer patients will respond to a certain drug treatment. The test will couple Key Genomics coexpression extrapolation, or COXEN, predictive algorithm with Transgenomics DNA mutation detection analysis technology to predict epithelial carcinoma of the ovary.
GenomeWeb News: Transgenomic, Key Genomics Teaming on Ovarian Cancer Treatment Test
0 comments :
Post a Comment